Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

Dopamine receptor 3 might be an essential molecule in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity.

Chen Y, Ni YY, Liu J, Lu JW, Wang F, Wu XL, Gu MM, Lu ZY, Wang ZG, Ren ZH.

BMC Neurosci. 2013 Jul 31;14:76. doi: 10.1186/1471-2202-14-76.

PMID:
23902361
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.

Moon M, Kim HG, Hwang L, Seo JH, Kim S, Hwang S, Kim S, Lee D, Chung H, Oh MS, Lee KT, Park S.

Neurotox Res. 2009 May;15(4):332-47. doi: 10.1007/s12640-009-9037-x. Epub 2009 Mar 17.

PMID:
19384567
[PubMed - indexed for MEDLINE]
3.

Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice.

Boeckler F, Leng A, Mura A, Bettinetti L, Feldon J, Gmeiner P, Ferger B.

Biochem Pharmacol. 2003 Sep 15;66(6):1025-32.

PMID:
12963489
[PubMed - indexed for MEDLINE]
4.

Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.

Joyce JN, Woolsey C, Ryoo H, Borwege S, Hagner D.

BMC Biol. 2004 Oct 11;2:22.

PMID:
15473914
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.

Goldberg NR, Fields V, Pflibsen L, Salvatore MF, Meshul CK.

Neurobiol Dis. 2012 Mar;45(3):1051-67. doi: 10.1016/j.nbd.2011.12.024. Epub 2011 Dec 14.

PMID:
22198503
[PubMed - indexed for MEDLINE]
6.

Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

L'Episcopo F, Tirolo C, Caniglia S, Testa N, Serra PA, Impagnatiello F, Morale MC, Marchetti B.

J Neuroinflammation. 2010 Nov 23;7:83. doi: 10.1186/1742-2094-7-83.

PMID:
21092260
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.

Lao CL, Kuo YH, Hsieh YT, Chen JC.

Neurotox Res. 2013 Nov;24(4):523-31. doi: 10.1007/s12640-013-9408-1. Epub 2013 Jul 3.

PMID:
23820985
[PubMed - indexed for MEDLINE]
8.

Quantitative assessment of gait and neurochemical correlation in a classical murine model of Parkinson's disease.

Wang XH, Lu G, Hu X, Tsang KS, Kwong WH, Wu FX, Meng HW, Jiang S, Liu SW, Ng HK, Poon WS.

BMC Neurosci. 2012 Nov 14;13:142. doi: 10.1186/1471-2202-13-142.

PMID:
23151254
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Attenuation of MPTP-induced neurotoxicity and locomotor dysfunction in Nucling-deficient mice via suppression of the apoptosome pathway.

Teng X, Sakai T, Liu L, Sakai R, Kaji R, Fukui K.

J Neurochem. 2006 May;97(4):1126-35.

PMID:
16686692
[PubMed - indexed for MEDLINE]
10.

The mouse MPTP model: gene expression changes in dopaminergic neurons.

Kühn K, Wellen J, Link N, Maskri L, Lübbert H, Stichel CC.

Eur J Neurosci. 2003 Jan;17(1):1-12.

PMID:
12534964
[PubMed - indexed for MEDLINE]
11.

Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.

Li C, Biswas S, Li X, Dutta AK, Le W.

J Neurosci Res. 2010 Aug 15;88(11):2513-23. doi: 10.1002/jnr.22405.

PMID:
20623619
[PubMed - indexed for MEDLINE]
12.

Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Jackson-Lewis V, Jakowec M, Burke RE, Przedborski S.

Neurodegeneration. 1995 Sep;4(3):257-69.

PMID:
8581558
[PubMed - indexed for MEDLINE]
13.

Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.

Jiang H, Li LJ, Wang J, Xie JX.

Exp Neurol. 2008 Aug;212(2):532-7. doi: 10.1016/j.expneurol.2008.05.006. Epub 2008 May 20.

PMID:
18577498
[PubMed - indexed for MEDLINE]
14.

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E, Strong R, Lutz B, Marsicano G, Roberts JL, Giuffrida A.

Eur J Neurosci. 2009 Jun;29(11):2177-86. doi: 10.1111/j.1460-9568.2009.06764.x. Epub 2009 May 21.

PMID:
19490092
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Richardson JR, Caudle WM, Guillot TS, Watson JL, Nakamaru-Ogiso E, Seo BB, Sherer TB, Greenamyre JT, Yagi T, Matsuno-Yagi A, Miller GW.

Toxicol Sci. 2007 Jan;95(1):196-204. Epub 2006 Oct 12.

PMID:
17038483
[PubMed - indexed for MEDLINE]
Free Article
16.

Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS.

J Neurosci. 2004 Feb 25;24(8):2045-53.

PMID:
14985447
[PubMed - indexed for MEDLINE]
Free Article
17.

SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.

Ago Y, Kawasaki T, Nashida T, Ota Y, Cong Y, Kitamoto M, Takahashi T, Takuma K, Matsuda T.

Neuropharmacology. 2011 Dec;61(8):1441-51. doi: 10.1016/j.neuropharm.2011.08.041. Epub 2011 Sep 2.

PMID:
21903118
[PubMed - indexed for MEDLINE]
18.

Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions.

Gibrat C, Saint-Pierre M, Bousquet M, Lévesque D, Rouillard C, Cicchetti F.

J Neurochem. 2009 Jun;109(5):1469-82. doi: 10.1111/j.1471-4159.2009.06072.x. Epub 2009 Mar 28.

PMID:
19457163
[PubMed - indexed for MEDLINE]
19.

Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.

González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, Pacheco R.

J Immunol. 2013 May 15;190(10):5048-56. doi: 10.4049/jimmunol.1203121. Epub 2013 Apr 15.

PMID:
23589621
[PubMed - indexed for MEDLINE]
Free Article
20.

The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.

Drouin-Ouellet J, Gibrat C, Bousquet M, Calon F, Kriz J, Cicchetti F.

J Neuroinflammation. 2011 Oct 11;8:137. doi: 10.1186/1742-2094-8-137.

PMID:
21989292
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk